Pfizer proposes to expand vaccine trial against advanced coronavirus


Pfizer’s global headquarters are located in Midtown Manhattan, New York.Drew Angerer | Getty Images

Pfizer and German biotech company BioNTech announced on Saturday that they have submitted a proposal to the United States Food and Drug Administration to expand the phase three trial of its coronavirus vaccine to 44,000 participants, a significant increase from its previous goal of 30,000.The companies, which are developing the vaccine together, said in a statement that the trial is proceeding as planned and that they expect to have recruited 30,000 participants by next week.

–CNBC Meg Tirrell contributed to this report.


Please enter your comment!
Please enter your name here